FDA clears Elscint's TransACT protocol

Article

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct

Elscint has received 510(k) clearance for its TransACT attenuation-correctiontechnique for the CardiaL 90° dual-head gamma camera. Clinicianshave been testing TransACT at Duke University Medical Center inDurham, NC, for its ability to correct inferior wall artifactscommon in myocardial imaging with thallium. The company is planningto adapt the technique for the adjustable-angle Varicam cameraas well.

Elscint also announced this month that it has received clearancefor its 2-tesla Prestige MRI scanner.

Recent Videos
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Related Content
© 2025 MJH Life Sciences

All rights reserved.